A statistically significant difference in favour of tenofovir disoproxil 245 mg (as fumarate) was seen in the time-weighted average change from baseline at week 24 (DAVG24) for CD4 count (+13 cells/ mm3 for tenofovir disoproxil 245 mg (as fumarate) versus -11 cells/ mm3 for placebo, p-value = 0.0008).